A genome-wide cfDNA methylation enrichment method (cfMeDIP-seq) enables response monitoring using plasma alone, avoiding ...
Please provide your email address to receive an email when new articles are posted on . Patients with limited-stage small cell lung cancer with ctDNA positivity after chemotherapy had significant ...
“Incorporating ctDNA into the decision-making process helps refine who can safely keep their bladder,” Ghatalia, associate professor, Department of Hematology/Oncology, at Fox Chase Cancer Center in ...
Dr. Rita Mukhtar and Dr. Joshua K. Sabari discuss the role of ctDNA to guide surgical decision-making after neoadjuvant chemo in breast cancer treatment. Dr. Rita Mukhtar and Dr. Joshua K. Sabari sat ...
New data from two large studies presented at the 2025 ASCO Gastrointestinal Cancers Symposium (GICS) 2025 provide evidence of the clinical utility of circulating tumor DNA (ctDNA) testing in ...
The organization presented data aggregated from multiple clinical trials to explore ctDNA's potential as a surrogate endpoint predictive of treatment benefit in lung and other cancers.
Postoperative circulating tumor DNA (ctDNA) positivity strongly predicts worse survival in stage III colon cancer, with ctDNA-positive patients showing sixfold higher recurrence risk. Among ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results